MindRank Recognized as a Potential Unicorn and Rising Star in Biotech, Advances AI-Driven Drug Candidate MDR-001 into Phase IIb Trials
MindRank
AI Drug Developer
As October draws to a close, "MindRank" has gained new accolades by being consecutively listed on two innovative enterprise lists.
Potential Unicorn Enterprises in China
On October 24, 2024, Great Wall Strategy Consulting released the "GEI China Potential Unicorn Enterprise Research Report 2024." MindRank was selected for its leading innovation capabilities in the AI pharmaceuticals field."Potential Unicorn Companies in China."
Great Wall Strategy Consulting is the earliest think tank institution in China to research and release the Unicorn series rankings, and has been publishing the list of China's potential unicorn companies and research reports for five consecutive years since 2020. The report shows,The number of potential unicorn companies in China increased to 783 in 2023, with 301 new additions.Potential unicorn companies are mainly distributed in sectors such as integrated circuits, innovative drugs, and digital healthcare, with the proportion of companies in frontier technology fields exceeding 85%.
High-Tech and High-Growth Enterprises in China's Biopharmaceutical Industry
On October 25, 2024, the science and technology innovation service platform Enterprise Business Card released the 2024 Rising Stars series of enterprise rankings, and "MindRank" was selected."High-Tech and High-Growth Enterprises in China's Biomedical Industry in 2024"
Innovative companies, based on their insights into the industry's foresight and future development trends, create new technologies, products, and services that promote industrial upgrading and structural adjustment. The 2024 "Rising Stars" series of enterprise rankings by Qimingpian evaluates companies comprehensively from three aspects: financing situation, operational performance, and market influence using its proprietary data platform, aiming to identifyNon-listed innovative enterprises with strong growth and good development potential across various industries in China,Leverage the leading and exemplary effects of the listed companies in the industry and region.
To enable people to live healthier lives,It is the greatest vision of "MindRank." Guided by this vision, the team continuously iterates and upgrades its self-developed industrial-grade one-stop AI pharmaceutical platform, pushing its core modules to reach internationally leading standards. At the same time, it expands AI drug discovery technologies into areas such as molecular glues and large molecules, actively exploring drug discovery for more difficult-to-drug targets and novel targets.
Currently, the company's self-developed GLP-1RA small molecule oral new drugMDR-001 has successfully entered Phase IIb clinical research,Multiple innovative drugs targeting tumors and metabolism are undergoing IND-Enabling stage research, and the "MindRank" team will continue to advance more high-quality drugs toward clinical validation.
About MindRank
MindRank is a clinical-stage AI-driven innovative drug discovery company. The company's vision is to continuously deliver differentiated and high clinical value drug candidates by promoting the integration of various cutting-edge technologies in artificial intelligence and new drug development, thereby helping more lives regain health.
MindRank's AI pharmaceutical solutions were rated as one of the "11 most important AI drug R&D breakthrough achievements globally from 2018 to 2020" by the authoritative European and American institution, Deep Pharma Intelligence. In 2023, it was included in Forbes' "Forbes Asia 100 to Watch" list, with only 11 startups from mainland China making the list. In 2024, it was selected for Fortune magazine's IMPACT Enterprise List as one of "China's most socially influential startups."
Related Reading:
MindRank Selected as One of the Top 100 Companies to Watch in the 2023 Forbes Asia-Pacific Region
For more information, please visit the website: www.mindrank.ai
Cooperation: bd@mindrank.ai
Other: info@mindrank.ai